BioSpace News Archive

OraSure Technologies, Inc. has scheduled its regular earnings conference call covering 2019 fourth quarter financial results, updated financial guidance and certain business developments for 5:00 pm ET on Wednesday, February 19, 2020..

Dual targeting of neurotoxic tau and amyloid beta is a promising area of therapy development for Alzheimer’s; ProMIS to present data on novel antibodies for toxic tau

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced several poster presentations, including interim data from its Phase I/II trial of RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II)

Net sales were $10.2 billion, down 15% versus pro forma results in the year-ago period, primarily driven by lower local prices in all operating segments due to a decline in global energy prices.

TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announces the appointment of Peter Murphy to the newly created role of Chief Commercial Officer.

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced the appointment of two new Vice Presidents in its Commercial Operations group to support the potential launch, if approved, of YCANTH™ (cantharidin 0.7% topical solution),

As you may recall, we believe that the sensor market on the whole is a gamechanger like drones, cannabis, bit-coin, and the like.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic dermatitis, psoriasis, asthma and acne, announced today that the Company, after further evaluation under its Commercial Evaluation Sublicense and Option Agreement with the University of Maryland, Baltimore (UMB) and Isoprene Pharmaceuticals Inc.

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 28, 2019.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, presented preclinical results of TNX-801 to potentially prevent smallpox and monkeypox in a poster at the 2020 ASM Biothreats Conference held January 28-30, 2020 in Arlington, Va.